Abstract
Perhaps it was inevitable. What began as a dispute between scientists at the Paris-based Institut Curie and Myriad Genetics Inc. of Salt Lake City over testing rights in France for the putative breast cancer genes BRCA1 and BRCA2 has spilled over to much of Western Europe.

This publication has 0 references indexed in Scilit: